ClinicalTrials.gg
RecruitingNCT07594977Updated Jun 15, 2026

Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers

A Phase 1 interventional study of 4-MUST in Chronic Cholecystitis and Biliary Dyskinesia, sponsored by Valenta Pharm JSC. Recruiting at 1 site in Russia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Valenta Pharm JSC · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2026, registered May 2026).
  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This open-label study will evaluate the effect of food on the bioavailability of a single dose of 4-MUST, tablets, 128 mg. Additionally, the study will assess the pharmacokinetics, safety, and tolerability of 4-MUST, tablets, 128 mg following both single and multiple oral dose administration.

02

Conditions studied

  • Chronic Cholecystitis
  • Biliary Dyskinesia
03

In context

Lead sponsor

Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary, personally signed ICF obtained prior to any study procedures;
  • Males and females aged 18 to 45 years (inclusive) of Caucasian race;
  • Confirmed healthy status based on the absence of abnormalities in clinical, laboratory, and diagnostic assessments specified in the protocol;
  • Blood pressure (BP): systolic blood pressure (SBP) from 99 to 129 mmHg (inclusive), diastolic blood pressure (DBP) from 70 to 89 mmHg (inclusive);
  • Heart rate (HR) from 60 to 89 beats/min (inclusive);
  • Respiratory rate (RR) from 12 to 20 per 1 minute (inclusive);
  • Body temperature from 36.0°C to 36.9°C (inclusive);
  • (BMI) of 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2, with body weight ≥ 55 kg for males and ≥ 45 kg for females;
  • Commitment to adhere to highly effective methods during the study participation period and for 30 days thereafter; documentation of negative urine pregnancy test for women of .

Noninclusion Criteria:

  • History of clinically significant allergic reactions;
  • to hymecromone and trimebutine and/or included in the study drug in anamnesis;
  • Drug intolerance to hymecromone and trimebutine and/or excipients included in the study drug in the anamnesis;
  • Hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption in the anamnesis;
  • Chronic diseases of the kidney, liver, gastrointestinal tract (GIT), cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, genitourinary and immune systems, as well as skin, hematopoietic and visual organs;
  • History of GI surgery (except for appendectomy at least 1 year prior to screening);
  • Diseases/conditions that, in the opinion of the investigator, may affect the absorption, distribution, metabolism, or excretion of the study drug;
  • Acute infectious diseases less than 4 weeks prior to screening;
  • Intake of drugs that have a significant effect on hemodynamics and drugs that affect liver function (barbiturates, omeprazole, cimetidine, etc.) less than 2 months before screening;
  • Regular intake of a medicine less than 2 weeks prior to screening and single intake of a medicine less than 7 days prior to screening (including over-the-counter medicines, vitamins, supplements, herbs);
  • Blood or plasma donation less than 3 months prior to screening;
  • Use of hormonal contraceptives (in women) less than 2 months prior to screening;
  • Use of depot injections of any medicine less than 3 months prior to screening;
  • Pregnancy or lactation period; positive pregnancy test for women of childbearing potential;
  • Women of childbearing potential who have had unprotected sexual intercourse with a non-sterilized male partner within 30 days prior to administration of the study drug;
  • Participation in another clinical trial less than 3 months prior to screening or concurrent with the present study;
  • Consumption of more than 10 units of alcohol per week during the month prior to study enrollment (1 unit of alcohol is equivalent to 500 mL of beer, 200 mL of wine, or 50 mL of spirits), or a history of alcoholism, drug dependence, or abuse of medicinal products;
  • Smoking more than 10 cigarettes per day currently, or a history of smoking the indicated number of cigarettes in the 6 months preceding screening; failure to agree to abstain from smoking for the duration of the hospital stay;
  • Consumption of alcohol, caffeine, and xanthine-containing products in the 7 days prior to taking the study drug;
  • Consumption of citrus fruits, cranberries, rose hips and products containing them, preparations or products containing St. John's wort - 7 days before taking the study drug;
  • Dehydration due to diarrhea, vomiting, or other cause within the last 24 hours prior to taking the study drug;
  • Positive blood test result for antibodies to (HIV) 1 and 2, antibodies to Treponema pallidum antigens, surface antigen (HBsAg), antibodies to virus antigens at screening;
  • Clinically significant abnormalities on (ECG) in the medical history and/or at screening;
  • Positive urinalysis for narcotics and potent drugs at screening;
  • Positive breath alcohol vapor test at screening;
  • Scheduling a hospital stay during the study period, for any reason other than hospitalization required by this protocol;
  • Failure or inability to comply with protocol requirements, follow protocol procedures, diet and activity regimen.
  • Belonging to a vulnerable population, including: students enrolled in medical, pharmaceutical, or dental educational institutions, clinical and laboratory assistants, pharmaceutical company employees, military personnel and prisoners, persons residing in residential care facilities, low-income and unemployed, minorities, homeless, vagrants, refugees, persons in foster care, persons unable to consent, and law enforcement officers;
  • Any other condition that, in the judgement of the Investigator, would preclude the volunteer's enrollment in the study or could lead to premature withdrawal from the study, including adherence to fasting regimens or special diets (e.g., vegetarian, vegan, or sodium-restricted diets) or lifestyle factors (e.g., night-shift work or extreme physical exertion)

Exclusion criteria

Exclusion criteria:

  • Voluntary withdrawal of the subject from the study;
  • Failure to comply with protocol requirements by the volunteer (e.g., missing scheduled study procedures, unauthorized use of prohibited medications, or violation of dietary or lifestyle restrictions);
  • Occurrence of any event or condition during the study that, in the investigator's judgement, may compromise the volunteer's safety (e.g., reactions);
  • Volunteers selected for participation in the study in violation of the inclusion/non-inclusion criteria;
  • Development of severe adverse event and/or a serious adverse event in a volunteer during the course of the study;
  • Volunteer is receiving or requires treatment that may affect the pharmacokinetic parameters of the study drug;
  • Missing collection of 2 or more consecutive blood samples or 3 x or more blood samples during the same Study Period;
  • Occurrence of vomiting/diarrhea within 6 h after administration of study drug;
  • Positive urine test for narcotics and potent drugs;
  • Positive breath alcohol test;
  • Positive pregnancy test in women;
  • Occurrence of any other circumstance that precludes conduct of the study in accordance with the protocol.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    AB sequence

    Cohort 1, Group 1 (sequence AB) will receive 3 tablets (384 mg) of the study drug under fasting conditions in Period I and under fed conditions in Period II.

    Drug: 4-MUST

  • Experimental
    BA sequence

    Cohort 1, Group 2 (sequence AB)will receive 3 tablets (384 mg) of the study drug under fed conditions in Period I and under fasting conditions in Period II.

    Drug: 4-MUST

  • Experimental
    Multiple dosing

    Cohort 2, Multiple dose: 3 tablets (384 mg) three times daily, 30 minutes before meals, for 3 consecutive days (with the last dose taken in the morning of Day 4).

    Drug: 4-MUST

Interventions

  • Drug4-MUST

    128 mg tablets containing trimebutine 4-methylumbelliferyl sulfate (4-MUST)

    Also known as: trimebutine 4-methylumbelliferyl sulfate

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics - Cmax

    Maximum plasma concentration (Cmax) of 4-MUST metabolites: trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  2. Pharmacokinetics - tmax

    Time to reach Cmax (tmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  3. Pharmacokinetics - AUC0-t

    Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  4. Pharmacokinetics - AUC0-inf

    Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  5. Pharmacokinetics - AUC ratio

    The ratio of the area under the concentration-time curve over the observation time to the calculated area under the concentration-time curve from zero to infinity

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  6. Pharmacokinetics - t1/2

    Elimination half-life (t1/2) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  7. Pharmacokinetics - kel

    Elimination constant (kel) of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  8. Pharmacokinetics - MRT

    Mean residence time (MRT) of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  9. Pharmacokinetics - Vd

    Volume of distribution of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  10. Pharmacokinetics - Cmax/AUC0-t

    The ratio of the maximum concentration to the area under the concentration-time curve during the observation period

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  11. Pharmacokinetics - f'

    f' - relative bioavailability (AUC(0-t)(fed)/AUC(0- t)(fasting))

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  12. Pharmacokinetics - f''

    f'' is the relative absorption rate (Cmax(fed)/Cmax(fasting))

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  13. Bioavailability - ratio of Cmax

    Ratio of geometric mean Cmax for trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  14. Bioavailability - ratio of AUC0-t

    Ratio of geometric mean AUC0-t for of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  15. Bioavailability - ratio of AUC0-inf

    Ratio of geometric mean AUC0-inf for of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)

    Time frame: From 0 to 48 hours (days 1-3 and 8-10)

  16. Pharmacokinetics (multiple dosing) - number of terminal timepoints

    number of points in the terminal logarithmic phase used to estimate the terminal elimination rate constant of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  17. Pharmacokinetics (multiple dosing) - Cmax

    Maximum plasma concentration (Cmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  18. Pharmacokinetics (multiple dosing) - tmax

    Time to reach Cmax (tmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  19. Pharmacokinetics (multiple dosing) - AUC0-t

    Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  20. Pharmacokinetics (multiple dosing) - AUC0-inf

    Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  21. Pharmacokinetics (multiple dosing) - AUCextr

    Extrapolated AUC of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  22. Pharmacokinetics (multiple dosing) - t1/2

    Elimination half-life (t1/2) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  23. Pharmacokinetics (multiple dosing) - kel

    Elimination constant (kel) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  24. Pharmacokinetics (multiple dosing) - MRT

    Mean residence time (MRT) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  25. Pharmacokinetics (multiple dosing) - Vd

    Volume of distribution of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  26. Pharmacokinetics (multiple dosing) - CL

    Clearance (CL) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 72 to 120 hours

  27. Pharmacokinetics (multiple dosing) - Cmax,ss

    Maximum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 72 hours

  28. Pharmacokinetics (multiple dosing) - tmax,ss

    Time to reach maximum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 72 hours

  29. Pharmacokinetics (multiple dosing) - tmin,ss

    Time to reach minimum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 72 hours

  30. Pharmacokinetics (multiple dosing) - Cmin,ss

    Minimum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 72 hours

  31. Pharmacokinetics (multiple dosing) - Cavg,ss

    Average plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 72 hours

  32. Pharmacokinetics (multiple dosing) - CL,ss

    Clearance at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide

    Time frame: From 0 to 72 hours

Secondary outcomes

  1. Adverse event type

    Adverse events will be assessed by complaints, results of physical examination, results of heart rate and blood pressure assessment, results of respiratory rate assessment, body temperature, laboratory monitoring (clinical blood count, biochemical blood count, urinalysis), electrocardiography; adverse events will be classified in accordance to MedDRA.

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  2. Adverse event frequency

    Number and frequency of adverse events registered during the study

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  3. Adverse event severety

    Severity of adverse events registered during the study, assessed using the Common Terminology Criteria for Adverse Events (CTCAE)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  4. Drop-outs associated with adverse events

    The number of cases of early termination of participation in the study due to the development of adverse events and/or serious adverse events associated with the study drug

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  5. Physical examination results - cardiovascular system

    An assessment of the condition of the cardiovascular system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  6. Physical examination results - respiratory system

    An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  7. Physical examination results - digestive tract

    An assessment of the condition of the digestive tract on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  8. Physical examination results - endocrine system

    An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  9. Physical examination results - musculoskeletal system

    An assessment of the condition of the musculoskeletal system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  10. Physical examination results - nervous system

    An assessment of the condition of the nervous system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  11. Physical examination results - sensory systems

    An assessment of the condition of the sensory systems on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  12. Physical examination results - skin/visible mucous membranes

    An assessment of the condition of the skin/visible mucous membranes on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  13. Physical examination results - genitourinary system

    An assessment of the condition of the genitourinary system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  14. Safety and Tolerability: vital signs - systolic blood pressure

    Systolic blood pressure (SBP, mmHg)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  15. Safety and Tolerability: vital signs - diastolic blood pressure

    Diastolic blood pressure (DBP, mmHg)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  16. Safety and Tolerability: vital signs - heart rate

    Heart rate (HR, bpm)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  17. Safety and Tolerability: vital signs - respiratory rate

    Respiratory rate (breaths per minute)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  18. Safety and Tolerability: vital signs - body temperature (Celsius temperature scale)

    Body temperature (Celsius temperature scale)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  19. Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6): heart rate (beats per minute)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  20. Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6): PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  21. Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  22. Safety and Tolerability: 12-lead electrocardiogram (ECG) - QT interval

    12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QT interval (distance from the beginning of the QRS complex to the end of the T wave)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  23. Safety and Tolerability: clinical blood test - hemoglobin

    Hemoglobin (g/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  24. Safety and Tolerability: clinical blood test - hematocrit

    Hematocrit (%)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  25. Safety and Tolerability: clinical blood test - red blood cell count

    Red blood cell count (cells/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  26. Safety and Tolerability: clinical blood test - platelet count

    Platelet count (cells/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  27. Safety and Tolerability: clinical blood test - leukocyte count

    Leukocyte count (cells/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  28. Safety and Tolerability: clinical blood test - erythrocyte sedimentation rate

    Erythrocyte sedimentation rate (mm/h)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  29. Safety and Tolerability: clinical blood test - myelocytes

    Leukocyte formula (myelocytes, %)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  30. Safety and Tolerability: clinical blood test - band neutrophils

    Leukocyte formula (band neutrophils, %)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  31. Safety and Tolerability: clinical blood test - segmented neutrophils

    Leukocyte formula (segmented neutrophils, %)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  32. Safety and Tolerability: clinical blood test - eosinophils

    Leukocyte formula (eosinophils, %)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  33. Safety and Tolerability: clinical blood test - basophils

    Leukocyte formula (basophils, %)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  34. Safety and Tolerability: clinical blood test - monocytes

    Leukocyte formula (monocytes, %)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  35. Safety and Tolerability: clinical blood test - lymphocytes

    Leukocyte formula (lymphocytes, %)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  36. Safety and Tolerability: blood chemistry - glucose

    Glucose concentration (mmol/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  37. Safety and Tolerability: blood chemistry - cholesterol

    Total cholesterol concentration (mmol/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  38. Safety and Tolerability: blood chemistry - total protein

    Total protein in blood serum (g/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  39. Safety and Tolerability: blood chemistry - bilirubin

    Total bilirubin concentration (micromol/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  40. Safety and Tolerability: blood chemistry - creatinine

    Creatinine concentration (micromol/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  41. Safety and Tolerability: blood chemistry - alkaline phosphatase

    Alkaline phosphatase activity (U/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  42. Safety and Tolerability: blood chemistry - alanine transaminase

    Alanine transaminase activity (U/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  43. Safety and Tolerability: blood chemistry - aspartate transaminase

    Aspartate transaminase activity (U/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  44. Safety and Tolerability: urinalysis - specific gravity

    Specific gravity of the urine

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  45. Safety and Tolerability: urinalysis - color

    Color of the urine

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  46. Safety and Tolerability: urinalysis - transparency

    Transparency of the urine

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  47. Safety and Tolerability: urinalysis - pH

    pH of the urine

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  48. Safety and Tolerability: urinalysis - protein

    Protein concentration (g/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  49. Safety and Tolerability: urinalysis - glucose

    Glucose concentration (mmol/L)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  50. Safety and Tolerability: urinalysis - red blood cells

    Red blood cell content (number in sight)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  51. Safety and Tolerability: urinalysis - white blood cells

    White blood cell content (number in sight)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  52. Safety and Tolerability: urinalysis - casts

    Presence of casts (Yes/No)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  53. Safety and Tolerability: urinalysis - mucus

    Presence of mucus (Yes/No)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

  54. Safety and Tolerability: urinalysis - bacteria

    Presence of bacteria (Yes/No)

    Time frame: From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

07

Study locations

1 of 1 sites recruiting
  • I.M. Sechenov First Moscow State Medical University
    Moscow, 119991, Russia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartActual
Jan 26, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07594977
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Jan 26, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion